Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1β on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: Differential effect on C-reactive protein production

Blood

Volumn 93, Issue 4, 1999, Pages 1299-1307

  Gabay, Cem ^a,b   Porter, Brandon ^a   Guenette, Denis ^a   Billir, Bahri ^a   Arend, William P ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIVER CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TRANSLATION INITIATION;

EID: 0033557933     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.4.1299.404k26_1299_1307     Document Type: Article

References (38)

1. Gabay C, Kushner I: The acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1998 (in press)
2. Gabay C, Smith MF Jr, Eidlen D, Arend WP: Interleukin-1 receptor antagonist is an acute-phase protein. J Clin Invest 99:2930, 1997
3. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamoka T, Paul WE: Identification of a T cell-derived B cell growth factor distinct from interleukin-2. J Exp Med 155:914, 1982
4. Brown MA, Pierce JH, Watson CJ, Fiaco J. Ihle JN, Paul WE: B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell 50:809, 1987
5. Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but upregulates gene expression and synthesis of interleukin I receptor antagonist. Proc Natl Acad Sci USA 89:4076, 1992
6. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA: Potential anti-inflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 86:3803, 1989
7. Standiford TJ, Strieter RM, Chensue SW, Westwick J, Kasahara K, Kunkel SL: IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol 145:1435, 1990
8. Zurawski G, De Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19, 1994
9. Loyer P, Ilyin G, Razzak ZA, Banchereau J, Dezier J-F, Campion J-P, Guguen-Guillouzo C, Guillouzo A: Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 336:215, 1993
10. Grunteld C, Soued M, Adi S, Moser AH, Fiers W, Dinarello CA. Feingold KR: Interleukin 4 inhibits stimulation of hepatic lipogenesis by tumor necrosis factor α, interleukin 1, and interleukin 6 but not by interferon-α1. Cancer Res 51:2803, 1991
11. Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne P-A: Soluble interleukin-6 receptor strongly increases the production of acute-phase proteins by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol 25:2378, 1995
12. Gabay C, Genin B, Mentha G. Iynedjian PB, Roux-Lombard P, Guerne P-A: IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin Exp Immunol 100:306, 1995
13. Gabay C, Porter B, Fantuzzi G. Arend WP: Mouse interleukin-1 receptor antagonist (IL-1Ra) isoforms. cDNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1Ra in vivo. J Immunol 159:5905, 1997
14. Malyak M, Guthridge JM, Hance KR, Dower SK, Freed JH, Arend WP: Characterization of a low molecular weight isotorm of interleukin-1 receptor antagonist. J Immunol 161:1997, 1998
15. Butcher C. Steinkasserer A, Tejura S, Lennard AC: Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist. J Immunol 153:701, 1996
16. Mikita T, Campbell D, Wu P, Williamson K, Schindler U: Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol Cell Biol 16:5811, 1996
17. Koehler L, Alliger P, Minty A, Caput D, Ferrara P, Hoell-Neugebauer B. Rank G, Rieber EP: Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL4 sharing DNA binding motif with an interferon-γ-induced nuclear binding factor. FEBS Lett 345:187, 1994
18. Izuhara K, Heike T, Otsuka T, Yamaoka K, Mayumi M, Imamura T, Niho Y, Harada N: Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X-linked severe combined immunodeficiency patients. J Biol Chem 271:619, 1996
19. Ohmori Y, Smith MF Jr. Hamilton TA: IL-4-induced expression of the IL-1 receptor antagonist gene is mediated by STAT6. J Immunol 157:2058, 1996
20. Lentsch AB, Shanley TP, Sarmu V, Ward PA: In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J Clin Invest 100:2443, 1997
21. Donnelly RP, Crofford LJ, Freeman SL, Buras J, Remmers E, Wilder RL, Fenton MJ: Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-κB activity in monocytes and tibroblasts. J Immunol 151:5603, 1993
22. lademarco MF, Barks JL, Dean DC: Regulation of vascular cell adesion molecule-1 expression by IL-4 and TNF-α in cultured endothelial cells. J Clin Invest 95:264, 1995
23. Miossec P, Van den Berg W: Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 40:2105, 1997
24. Sugiyama E, Taki H, Kuroda A, Mino T. Yamashita N, Kubayashi M: Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclooxygenase I. Ann Rheum Dis 55:375, 1996
25. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-1 Ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151:4344, 1993
26. Bessis N, Beissier MC, Ferrara P, Blankenstein T, Fradelizi D: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 26:2399, 1996
27. Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, Van den Berg WB: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Arthritis Rheum 40:249, 1997
28. Colotta F, Sironi M, Borre A, Luini W, Maddalena F, Mantovani A: Interleukin 4 amplifies monocyte chemotactic protein and interleukin 6 production by endolhelial cells. Cytokine 4:24, 1992
29. Marie C, Pitton C, Fitting C, Cavaillon J-M: IL-10 and IL-4 synergize with TNF-α to induce IL-1ra production by human neutro-phils. Cytokine 8:147, 1996
30. Gabay C, Gay-Crosier F, Roux-Lombard P, Meyer O, Guerne P-A, Vischer T, Dayer J-M: Elevated scrum levels of interleukin-1 receptor antagonist in polymyositis-dermatomyositis: A biological marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37:1744, 1994
31. Suzuki H, Takemura H, Kashiwagi H: Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Arthritis Rheum 38:1055, 1996
32. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer J-M, Vischer T, Yazici H, Guerne P-A: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24:303, 1997
33. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/WF1 mice. J Exp Med 179:395, 1994
34. Hagiwara E, Adams EM, Plotz PH, Klinman DM: Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyositis. Clin Exp Rheum 14:485, 1996
35. Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B: Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101. Association with IL-10 inhibition and increase in TNF-α levels. J Immunol 159:2658, 1997
36. Erb KJ, Rüger B. Von Brevern M, Ryffel B, Schimpl A, Rivett K: Constitutive expression of interleukin (IL)-4 in vivo causes autoimmunetype disorders in mice. J Exp Med 185:329, 1997
37. Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon gamma levels in sera from patients with scleroderma. Arthritis Rheum 35:67, 1992
38. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328, 1997